You're right. Our particular pack of shorts are here as an assignment, to keep the stock price depressed so as to dishearten us longs into accepting a lowball offer, and to indirectly discredit the company in the bargain. How many of us have tried to clue friends in about this company and gotten a "You gotta be kidding me" response the second they see the stock price?

Their overriding goal is to keep this drug and this company as out of public awareness as possible, thus keeping the volume down. Without low volume they are screwed. JL knows this, thus his multifront campaign to loft leronlimab and CytoDyn into the respectibility they deserve. Get papers out there, get studies running, get licensure/partnership agreements inked. I'm betting on him.